Patents Issued in August 18, 2020
  • Patent number: 10745386
    Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 18, 2020
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Huiping Zhao
  • Patent number: 10745387
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 18, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Patent number: 10745388
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 18, 2020
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Wenqing Yao
  • Patent number: 10745389
    Abstract: Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: August 18, 2020
    Assignees: CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD., CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD, CSTONE PHARMACEUTICALS
    Inventors: Hao Wu, Changqing Wei, Qiang Guo, Guifen Zhang, Bin Liu, Yonggang Liao, Yao Xiao, Shuhui Chen
  • Patent number: 10745390
    Abstract: Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Furthermore, such compounds are useful as probes for identifying defects in mitochondrial metabolism, mitochondrial iron accumulation, cellular stress among other mitochondrial diseases and helping to identify compounds active in overcoming such defects.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: August 18, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Robert B. Wilson, Maria Grazia Cotticelli, Phillip A. Benedetti, Amos Smith, Jason E. Melvin, Donna M Huryn
  • Patent number: 10745392
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 18, 2020
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Kristen Nicole Burford, Thilo Focken, Verner Alexander Lofstrand, Michael Scott Wilson, Alla Yurevna Zenova
  • Patent number: 10745393
    Abstract: The present disclosure relates to compounds which function as small molecule fluorescent probes which aid in recognition of specific sequences in DNA and detection of A? aggregates. Probes/dyes of the instant disclosure are specific to AT-rich sequences of DNA and A? aggregates. These small organic dyes/probes are capable of exhibiting switch-on fluorescence and play an important role in fluorescence spectroscopy, diagnostics, imaging and biomedical applications.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 18, 2020
    Assignee: JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH
    Inventors: Govindaraju Thimmaiah, Nagarjun Narayanaswamy, Kolla Rajasekhar
  • Patent number: 10745394
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang, Ioanna Stergiades, Priscilla M. Van Dyke
  • Patent number: 10745395
    Abstract: The present invention relates to compounds of the following formula (I), wherein: m represents an integer being equal to 0, 1, 2, 3, 4, 5 or 6, X represents a simple bond or a radical —CHR1 wherein R1 represents:—a hydrogen atom, or—a linear or branched, possibly interrupted by up to 3 heteroatoms selected from O, S or N and/or possibly substituted, (C1-C12)-alkyl, R2, R3 and R4 represent independently from each other:—a hydrogen atom, or—a linear or branched (C1-C12-alkyl or (C1-C12)-acyl R5 represents:—a hydrogen atom, or—a linear or branched, possibly substituted, (C1-C13)-alkyi possibly substituted and possibly interrupted by up to 3 heteroatoms selected from O, S or N, R6 represents:—a hydrogen atom, or—a linear or branched possibly substituted (C1-C12)-alkyl, possibly substituted and possibly interrupted by up to 3 heteroatoms selected from O, S or N, for their use as antibacterial drugs for the treatment and/or the prevention of infection(s) caused by biofilm-forming bacteria.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: August 18, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS, JAGIELLONIAN UNIVERSITY
    Inventors: Olivier Martin, Estelle Gallienne-Boivineau, Cyril Nicolas, Piotr B. Heczko, Grazyna Stochel, Magdalena Strus, Agnieszka Kyziol, Diana Mikolajczyk, Agnieszka Machul
  • Patent number: 10745396
    Abstract: Polycyclic derivatives of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 18, 2020
    Assignee: Syngenta Participations AG
    Inventors: Pierre Joseph Marcel Jung, Andrew Edmunds, Michel Muehlebach
  • Patent number: 10745397
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 18, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dinesh Barawkar, Anil M Deshpande, Santosh Patil, Yogesh Waman, Anil Panmand, Dilip Jadhav, Bheemashankar Kulkarni
  • Patent number: 10745398
    Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, A1, V, X and n have the meanings given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 18, 2020
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: David Wilcke, Rüdiger Fischer, Dominik Hager, Nina Kausch-Busies, Laura Hoffmeister, Kerstin Ilg, Ulrich Görgens, Daniela Portz, Andreas Turberg
  • Patent number: 10745399
    Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • Patent number: 10745400
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignees: Vanderbuilt University, La Jolla Pharmaceuticals Company
    Inventors: Corey R. Hopkins, Matthew Ritter, Charles C. Hong, Anish Vadukoot, Darren W. Engers, Craig W. Lindsley
  • Patent number: 10745401
    Abstract: The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: August 18, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hidefumi Yoshinaga, Yohei Ikuma, Junya Ikeda, Satoshi Adachi, Harunobu Mitsunuma, Yoshinori Aihara, Jeremy Besnard, Andrew Simon Bell
  • Patent number: 10745402
    Abstract: The application is directed to compounds of formula (I): and pharmaceutically acceptable salts, radiolabeled isomers, solvates, or hydrates thereof, wherein R1, R2, R3, X, and n are defined as set forth in the specification. The application is also directed to compounds of formulae II, I-a, I-a1, I-a2, I-b, and I-b1 and the pharmaceutically acceptable salts, radiolabeled isomers, solvates, and hydrates thereof. The application is also directed to use of Compounds of the present disclosure to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain Compounds of the present disclosure are especially useful for treating pain. In one embodiment, Compounds of the present disclosure exhibit less opioid-induced side effects (such as, euphoria or drug-liking).
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Patent number: 10745403
    Abstract: Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: August 18, 2020
    Assignee: PIMERA, INC.
    Inventor: Mustapha Haddach
  • Patent number: 10745404
    Abstract: The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 18, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Patent number: 10745405
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 18, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Donna A. A. Wilton, Mandy M. Loo, Ryan Hudson, Patrick J. Brassil
  • Patent number: 10745406
    Abstract: The present invention provides a process for the preparation of a compound of formula (VI), or a salt or derivative thereof, wherein R1 and R2 are independently C1-8 alkyl and * represents a stereocentre.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 18, 2020
    Assignee: EURO-CELTIQUE S.A.
    Inventors: Steve Whitelock, Deborah Phyllis Harding, Carl David Turner
  • Patent number: 10745407
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: August 18, 2020
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Patent number: 10745408
    Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 18, 2020
    Assignee: Tapestry Pharmaceuticals, Inc.
    Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
  • Patent number: 10745409
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noëlle Constance Pilatte
  • Patent number: 10745410
    Abstract: The present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds of formula (I) and their preparation methods. (I) In particular, the present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds useful as inhibitors of protein kinases, specifically CDC7 (cell division cycle 7) inhibitors.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 18, 2020
    Assignee: ZENJI RESEARCH LABORATORIES
    Inventor: Hai-Jun Zhang
  • Patent number: 10745411
    Abstract: Piperidino-dihydrothienopyrimidine sulfoxides of formula I wherein: Ring A is a 6-membered aromatic ring optionally comprising one or two nitrogen atoms and R is Cl and is located in the para-, meta-, or ortho-position of Ring A, S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: August 18, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pascale Arielle Jane-Josee Pouzet, Peter Nickolaus, Ulrike Werthmann, Rogelio P. Frutos, Bing-Shiou Yang, Soojin Kim, Jason Alan Mulder, Nitinchandra D. Patel, Chris Hugh Senanayake, Thomas Gabriel Tampone, Xudong Wei
  • Patent number: 10745412
    Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: August 18, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Luke Humphreys, Mark E. Scott
  • Patent number: 10745413
    Abstract: The present disclosure provides methods for synthesizing cantharidin and cantharidin derivatives.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 18, 2020
    Assignee: Verrica Pharmaceuticals, Inc.
    Inventors: Matthew Davidson, Steven R. Schow
  • Patent number: 10745414
    Abstract: The invention is relevant to chemistry of organic compounds, pharmacology and medicine, and is related to prevention and treatment of musculoskeletal diseases in human and animals associated with the disorder of bone and/or cartilage metabolism, particularly with such musculoskeletal diseases as osteoporosis, osteoarthritis and osteochondrosis, using a new salt form of 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazine-2-yl)amino)-2H-pyrido[3,2-b][1,4]oxazine-3(4H)-one. A salt of this compound with 4-methylbenzenesulfonic acid including its hydrates, solvates and polymorphic modifications of the salt, hydrates and solvates is featured with acceptable pharmacokinetic parameters and increased efficiency in the inhibition of Src-family kinases and Syk kinase, as well as other therapeutically significant kinases. This invention also covers pharmaceutical compositions containing therapeutically effective amount of the salt according to the invention.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 18, 2020
    Assignee: LIMITED “MOLECULAR TECHNOLOGIES”
    Inventors: Vladimir Evgenievich Nebolsin, Fedor Nikolaevich Novikov, Germes Grigorievich Chilov, Oleg Valentinovich Stroganov, Viktor Sergeevich Stroilov, Ilya Yurievich Titov
  • Patent number: 10745415
    Abstract: A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: August 18, 2020
    Assignee: AMRI ITALY S.R.L.
    Inventors: Paride Grisenti, Maria Argese, Daniele Pengo, Maria Donata Grilli, Emanuela Fumagalli, Giuseppe Motta
  • Patent number: 10745416
    Abstract: The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 18, 2020
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Evan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
  • Patent number: 10745417
    Abstract: The present invention relates to various compounds capable of temporarily hardening soft tissue for surgical suturing of the soft tissue. The compounds according to the present invention can temporarily increase the hardness or tension of soft tissue, thereby improving the suturing efficiency during suturing of the soft tissue, thereby preventing aftereffects or the like from occurring due to insufficient anastomosis. In addition, the compounds according to the present invention can temporarily increase the hardness or tension of soft tissue, particularly pancreas, thereby increasing the suturing efficiency during pancreaticoduodenectomy and effectively preventing pancreatic leakage.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 18, 2020
    Assignees: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Sang Chul Lee, Say June Kim, Kwan Young Jeong, Ok Hee Kim, Seok Jun Jo, Min Jin Yoo
  • Patent number: 10745418
    Abstract: Provided herein are supramolecular assemblies, the supramolecular assemblies comprising a racemic mixture of rigid macrocycles capable of interacting through [C—H . . . O] hydrogen bonds. Also provided herein are methods for preparing supramolecular assemblies, the method comprising providing a mixture of rigid macrocycles capable of interacting through [C—H . . . O] hydrogen bonds, the mixture of rigid macrocycles comprising a first rigid macrocycle enantiomer and a second rigid macrocycle enantiomer, and providing a solvent.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 18, 2020
    Assignee: Northwestern University
    Inventors: James Fraser Stoddart, Zhichang Liu
  • Patent number: 10745419
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 18, 2020
    Assignees: Loxo Oncology Inc., Array Biopharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Patent number: 10745420
    Abstract: The present invention relates to tetrahydropyrido[4,3-d]pyrimidine based compounds and methods which may be useful as inhibitors of ATR kinase for the treatment or prevention of cancer.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Jason Bryant Cross, Michael Garrett Johnson, Sarah Lively
  • Patent number: 10745421
    Abstract: The invention relates to a method for the cost-effective and environmentally friendly production of alkyl indium sesquichloride in high yield and with high selectivity and purity. The alkyl indium sesquichloride produced according to the invention is particularly suitable, also as a result of the high purity and yield, for the production, on demand, of indium-containing precursors in high yield and with high selectivity and purity. As a result of the high purity, the indium-containing precursors that can be produced are particularly suitable for metal organic chemical vapour deposition (MOCVD) or metal organic vapour phase epitaxy (MOVPE). The novel method according to the invention is characterised by the improved execution of the method, in particular a rapid process control. Owing to targeted and extensive use of raw materials that are cost-effective and have a low environmental impact, the method is also suitable for use on an industrial scale.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: August 18, 2020
    Assignee: UMICORE AG & CO. KG
    Inventors: Joerg Sundermeyer, Annika Frey, Wolf Schorn, Ralf Karch, Andreas Rivas-Nass, Eileen Woerner, Angelino Doppiu
  • Patent number: 10745422
    Abstract: An organometallic compound represented by Formulae 1, 2, or 3 below: wherein in Formulae 1, 2, and 3, groups and variables are the same as in the specification.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: August 18, 2020
    Assignees: SAMSUNG ELECTRONICS CO., LTD., SAMSUNG SDI CO., LTD.
    Inventors: Kyuyoung Hwang, Ohyun Kwon, Hyeonho Choi, Changwoo Kim, Seungjae Lee, Byoungki Choi
  • Patent number: 10745423
    Abstract: The present disclosure relates to a modifier, and more particularly, to a modifier including a compound represented by Formula 1, and a method of preparing the same. Such modifier exhibits excellent dispersibility via hydrogen bonding with an inorganic filler when mixed therewith. The present disclosure also relates to a modified conjugated diene-based polymer modified using the modifier and thus exhibiting excellent processability, high tensile strength, high wear resistance, low rolling resistance, and high wet skid resistance, and a method of preparing the modified conjugated diene-based polymer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: August 18, 2020
    Assignee: LG Chem, Ltd.
    Inventors: Min Sik Mun, No Ma Kim, Da Won Chai, Ho Young Lee
  • Patent number: 10745424
    Abstract: Methods for preparing a variety of ladderane precursors, ladderane compounds and ladderane lipids are provided. Also provided are methods of preparing a liposome from the ladderane lipids disclosed herein, and compositions thereof. Aspects of the invention include encapsulated one or more cargo moieties in the liposome or compositions thereof and use of the subject liposome compositions as vehicles in drug delivery, imaging, diagnostics and other medical applications. Aspects of the methods disclosed herein include administering a liposomal composition comprising a pharmaceutical agent to a subject under conditions sufficient to deliver the composition to a site of interest in the subject, and release the pharmaceutical agent from the liposomal composition.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 18, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Noah Burns, Steven R. Shuken, Jaron A. M. Mercer, Carolyn M. Cohen
  • Patent number: 10745425
    Abstract: Disclosed a chemiluminescence enhancer and a chemiluminescence immunodetection kit. The chemiluminescence enhancer is specifically a betaine and can be used for enhancing the luminance of a luminescent acridine substance. The chemiluminescence immunodetection kit comprising the chemiluminescence enhancer and a luminescent acridine substance features greatly enhanced luminescence signals and high detection sensibility, and can be widely applied to fields such as clinical diagnoses, scientific research, and sanitation analysis.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: August 18, 2020
    Assignee: SHENZHEN YHLO BIOTECH CO., LTD.
    Inventors: Kunhui Hu, Gang Wang, Fuzhen Xia, Chungen Qian, Liang Zhu, Dingbiao Zou
  • Patent number: 10745426
    Abstract: The present invention relates to a ligand compound, a catalyst system for olefin oligomerization and a method for oligomerizing an olefin using same. The catalyst system for olefin oligomerization according to the present invention exhibits high selectivity to 1-hexene or 1-octene while having excellent catalytic activity, thus enabling more efficient preparation of alpha-olefins.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: August 18, 2020
    Assignee: LG Chem, Ltd.
    Inventors: Seul Ki Im, Yong Ho Lee, Ki Soo Lee, Eun Ji Shin, Jin Young Park, Seok Pil Sa, Yoon Ki Hong
  • Patent number: 10745427
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, Minghong Zhong
  • Patent number: 10745428
    Abstract: Compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: August 18, 2020
    Assignees: IDENIX PHARMACEUTICALS LLC, MERCK SHARP & DOHME CORP.
    Inventors: Izzat Tiedje Raheem, Timothy J. Hartingh, John Schreier, Jean-Laurent Paparin
  • Patent number: 10745429
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold, as shown in Formula (I). The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (?S) instead of oxo (?O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: August 18, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10745430
    Abstract: Molybdenum complexes and use thereof in thin film deposition, such as CVD and ALD are provided herein. The molybdenum complexes correspond in structure to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen, alkyl, and trialkylsilyl; and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 is trialkylsilyl.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 18, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Shaun Garratt, Paul Williams
  • Patent number: 10745431
    Abstract: Metal complexes useful as emitters in OLEDs are disclosed.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: August 18, 2020
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Lichang Zeng, Michael S. Weaver, Eric A. Margulies, Zhiqiang Ji
  • Patent number: 10745432
    Abstract: An object of the present invention is to provide a crystal of 6?-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 18, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masahiro Abe, Tomoya Yokoi, Sotaro Sanpei, Kazunari Fukumoto, Hiroshi Nagano
  • Patent number: 10745433
    Abstract: The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: August 18, 2020
    Assignee: Taipei Medical University
    Inventors: Yun Yen, Jing-Ping Liou, Yun-Ru Liu
  • Patent number: 10745434
    Abstract: The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The prodrug of the present invention further comprises a solvate of the chemical compound shown in formula I, of an optical isomer thereof or of a pharmaceutically acceptable salt thereof. The prodrug of the present invention can treat viral infectious diseases, particularly hepatitis C viral infectious diseases.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: August 18, 2020
    Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.
    Inventors: Guocheng Wang, Huimin Wu
  • Patent number: 10745435
    Abstract: The invention relates to deoxynucleotide prodrugs and pharmaceutical preparations thereof. The deoxynucleotide prodrugs include, but are not limited to, The invention further relates to methods of treatment of a mitochondrial DNA (mtDNA) depletion syndrome (MDS) by administering a therapeutically-effective amount of a deoxynucleotide prodrug of the present invention.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 18, 2020
    Assignee: CERECOR, INC.
    Inventors: Stephen B. Thomas, Patrick J. Crutcher
  • Patent number: 10745436
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: August 18, 2020
    Assignee: Sage Therapeutics, Inc.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro